趋化因子(C-X-C 基序)配体 12 与胆囊癌进展相关,是一种新的独立的不良预后因素。

Chemokine (C-X-C motif) ligand 12 is associated with gallbladder carcinoma progression and is a novel independent poor prognostic factor.

机构信息

Department of Pathology, Cancer Research Institute, and Infection Signaling Network Research Center, Chungnam National University School of Medicine, Daejeon, Republic of Korea.

出版信息

Clin Cancer Res. 2012 Jun 15;18(12):3270-80. doi: 10.1158/1078-0432.CCR-11-2417. Epub 2012 May 2.

Abstract

PURPOSE

Although recent studies have suggested that chemokine (C-X-C motif) ligand 12 (CXCL12) is important in the progression of various malignancies, its role in gallbladder carcinoma (GBC) remains unknown. We investigated CXCL12 expression in GBC and its biologic and prognostic role in GBC tumorigenesis.

EXPERIMENTAL DESIGN

We examined CXCL12 expression in tumor specimens from 72 patients with GBC by immunohistochemistry and analyzed the correlation between CXCL12 expression and clinicopathologic factors or survival. The functional significance of CXCL12 expression was investigated by CXCL12 treatment and suppression of CXCR4, a major receptor of CXCL12, as well as by CXCL12 overexpression in in vitro and in vivo studies.

RESULTS

CXCL12 was differentially expressed in GBC tissues. CXCL12 expression was significantly associated with a high histologic grade (P = 0.042) and nodal metastasis (P = 0.015). Multivariate analyses showed that CXCL12 expression (HR, 8.675; P = 0.014) was an independent risk factor for patient survival. CXCL12 significantly increased anchorage-dependent and -independent growth, migration, invasion, adhesiveness, and survival of GBC cells in vitro, and these effects were dependent on CXCR4. Consistent with these results, overexpression of CXCL12 significantly promoted GBC tumorigenicity in a xenograft model.

CONCLUSIONS

Our results indicate that GBC cells express both CXCL12 and its receptor CXCR4, and CXCL12 may have a role in GBC progression through an autocrine mechanism. In addition, CXCL12 is a novel independent poor prognostic factor in patients with GBCs. Thus, targeting CXCL12 and CXCR4 may provide a novel therapeutic strategy for GBC treatment.

摘要

目的

虽然最近的研究表明趋化因子(C-X-C 基序)配体 12(CXCL12)在各种恶性肿瘤的进展中很重要,但它在胆囊癌(GBC)中的作用尚不清楚。我们研究了 CXCL12 在 GBC 中的表达及其在 GBC 肿瘤发生中的生物学和预后作用。

实验设计

我们通过免疫组织化学检查了 72 例 GBC 患者肿瘤标本中的 CXCL12 表达,并分析了 CXCL12 表达与临床病理因素或生存的相关性。通过 CXCL12 处理以及抑制 CXCL12 的主要受体 CXCR4,以及在体外和体内研究中过表达 CXCL12,研究了 CXCL12 表达的功能意义。

结果

CXCL12 在 GBC 组织中差异表达。CXCL12 表达与高组织学分级(P=0.042)和淋巴结转移(P=0.015)显著相关。多变量分析显示,CXCL12 表达(HR,8.675;P=0.014)是患者生存的独立危险因素。CXCL12 显著增加了 GBC 细胞在体外的锚定依赖性和非依赖性生长、迁移、侵袭、黏附性和生存能力,并且这些作用依赖于 CXCR4。与这些结果一致,过表达 CXCL12 显著促进了 GBC 在异种移植模型中的致瘤性。

结论

我们的结果表明,GBC 细胞表达 CXCL12 和其受体 CXCR4,并且 CXCL12 可能通过自分泌机制在 GBC 进展中发挥作用。此外,CXCL12 是 GBC 患者的一个新的独立不良预后因素。因此,靶向 CXCL12 和 CXCR4 可能为 GBC 治疗提供一种新的治疗策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索